| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Robert London | |
| P2860 | cites work | Instability and decay of the primary structure of DNA | Q22122361 |
| Analysis of the nucleic acid annealing activities of nucleocapsid protein from HIV-1. | Q40394716 | ||
| The retroviral enzymes | Q40394916 | ||
| Identification of amino acid residues in the human immunodeficiency virus type-1 reverse transcriptase tryptophan-repeat motif that are required for subunit interaction using infectious virions | Q40422838 | ||
| Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S | Q41145700 | ||
| Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain | Q41468615 | ||
| Homodimerization of the p51 subunit of HIV-1 reverse transcriptase. | Q41500267 | ||
| Human immunodeficiency virus type 1 (HIV-1) recombinant reverse transcriptase. Asymmetry in p66 subunits of the p66/p66 homodimer | Q41661545 | ||
| In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways | Q41668874 | ||
| Isolated HIV-1 core is active for reverse transcription. | Q41956340 | ||
| Kinetics of association and dissociation of HIV-1 reverse transcriptase subunits | Q41970869 | ||
| Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT. | Q42179793 | ||
| Evidence of interactions between the nucleocapsid protein NCp7 and the reverse transcriptase of HIV-1. | Q42598855 | ||
| Temperature-dependent equilibrium between the open and closed conformation of the p66 subunit of HIV-1 reverse transcriptase revealed by site-directed spin labelling. | Q42632779 | ||
| Human immunodeficiency virus type-1 reverse transcriptase and ribonuclease H as substrates of the viral protease | Q42842599 | ||
| Analysis of the backbone dynamics of the ribonuclease H domain of the human immunodeficiency virus reverse transcriptase using 15N relaxation measurements | Q43753343 | ||
| Insertion of a peptide from MuLV RT into the connection subdomain of HIV-1 RT results in a functionally active chimeric enzyme in monomeric conformation | Q43804442 | ||
| Glutamic residue 438 within the protease-sensitive subdomain of HIV-1 reverse transcriptase is critical for heterodimer processing in viral particles. | Q43908619 | ||
| Stabilization and activation of recombinant human immunodeficiency virus-1 reverse transcriptase-P66 | Q43940745 | ||
| Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors | Q44072183 | ||
| A reexamination of the propensities of amino acids towards a particular secondary structure: classification of amino acids based on their chemical structure. | Q44529130 | ||
| Cleavage of the HIV-1 p66 reverse transcriptase/RNase H by the p9 protease in vitro generates active p15 RNase H | Q44702825 | ||
| Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation | Q44926187 | ||
| Backbone dynamics of the RNase H domain of HIV-1 reverse transcriptase | Q44983725 | ||
| Error thresholds and the constraints to RNA virus evolution | Q44997148 | ||
| Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability | Q45001878 | ||
| Proteolytic release and crystallization of the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase | Q45218226 | ||
| Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation | Q45218379 | ||
| NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine. | Q45401764 | ||
| Analysis of amino acids in the beta7-beta8 loop of human immunodeficiency virus type 1 reverse transcriptase for their role in virus replication | Q45409561 | ||
| In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor | Q45419921 | ||
| The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs | Q45475260 | ||
| Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic intervention. | Q45860281 | ||
| Purification and characterization of heterodimeric human immunodeficiency virus type 1 (HIV-1) reverse transcriptase produced by in vitro processing of p66 with recombinant HIV-1 protease | Q45873021 | ||
| A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility | Q46295068 | ||
| Characterization of ribosomal frameshifting in HIV-1 gag-pol expression | Q46573916 | ||
| Effects of efavirenz binding on the subunit equilibria of HIV-1 reverse transcriptase | Q46964863 | ||
| A captured folding intermediate involved in dimerization and domain-swapping of GB1. | Q47311456 | ||
| Biochemistry. Metamorphic proteins | Q47610431 | ||
| Catalytic properties of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2. | Q54298285 | ||
| The accuracy of reverse transcriptase from HIV-1. | Q54738770 | ||
| Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 V | Q57480046 | ||
| Kinetics of RNA Degradation by Specific Base Catalysis of Transesterification Involving the 2‘-Hydroxyl Group | Q58001473 | ||
| Kinetic Analysis of Four HIV-1 Reverse Transcriptase Enzymes Mutated in the Primer Grip Region of p66 | Q59663006 | ||
| Characterization of the dimerization process of HIV-1 reverse transcriptase heterodimer using intrinsic protein fluorescence | Q59663050 | ||
| Relationship between enzyme activity and dimeric structure of recombinant HIV-1 reverse transcriptase | Q62898923 | ||
| Structure/function studies of HIV-1 reverse transcriptase: Dimerization-defective mutant L289K | Q72105897 | ||
| Factors affecting the dimerization of the p66 form of HIV-1 reverse transcriptase | Q73569162 | ||
| Structure--function relationships in HIV-1 Nef. | Q24522550 | ||
| Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. | Q24540388 | ||
| Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA | Q24545723 | ||
| The human immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapy | Q24607992 | ||
| HIV-1 frameshift efficiency is primarily determined by the stability of base pairs positioned at the mRNA entrance channel of the ribosome | Q24628718 | ||
| Retroviral intasome assembly and inhibition of DNA strand transfer | Q24629737 | ||
| VADAR: a web server for quantitative evaluation of protein structure quality | Q24672199 | ||
| Insertion of a small peptide of six amino acids into the beta7-beta8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities | Q24796883 | ||
| Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates | Q24812175 | ||
| Fusion of mature HIV-1 particles leads to complete release of a gag-GFP-based content marker and raises the intraviral pH | Q27309923 | ||
| The evolution of genome compression and genomic novelty in RNA viruses | Q27481078 | ||
| Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase | Q27628304 | ||
| Solution structure of the RNase H domain of the HIV-1 reverse transcriptase in the presence of magnesium | Q27640327 | ||
| Snapshots of a Y-family DNA polymerase in replication: substrate-induced conformational transitions and implications for fidelity of Dpo4 | Q27650489 | ||
| Structure of HIV-1 Reverse Transcriptase with the Inhibitor β-Thujaplicinol Bound at the RNase H Active Site | Q27658584 | ||
| Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex | Q27659857 | ||
| Crystal Structure of tert -Butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in Complex with HIV-1 Reverse Transcriptase (RT) Redefines the Elastic Limits of the Non-nucleoside Inhibitor-Binding Pocket | Q27667348 | ||
| HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism | Q27676835 | ||
| Selective unfolding of one Ribonuclease H domain of HIV reverse transcriptase is linked to homodimer formation | Q27681926 | ||
| Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease | Q27696384 | ||
| Crystal structure of rat DNA polymerase beta: evidence for a common polymerase mechanism | Q27729370 | ||
| 2.2 A resolution structure of the amino-terminal half of HIV-1 reverse transcriptase (fingers and palm subdomains) | Q27729416 | ||
| Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors | Q27729428 | ||
| Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms | Q27733392 | ||
| Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance | Q27766086 | ||
| Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution | Q27766103 | ||
| Empirical Predictions of Protein Conformation | Q28300310 | ||
| Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine | Q28370846 | ||
| Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication | Q28378825 | ||
| S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1 | Q28379544 | ||
| Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol | Q28469069 | ||
| Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients | Q28472255 | ||
| Gag-Pol processing during HIV-1 virion maturation: a systems biology approach | Q28533696 | ||
| Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor | Q29547710 | ||
| HIV-1 accessory proteins--ensuring viral survival in a hostile environment | Q29619538 | ||
| Vinylogous ureas as a novel class of inhibitors of reverse transcriptase-associated ribonuclease H activity | Q33373484 | ||
| An open and closed case for all polymerases. | Q33658307 | ||
| The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage site | Q33698586 | ||
| Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy | Q33851627 | ||
| Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition | Q33896402 | ||
| Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer | Q33911895 | ||
| High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations | Q33911980 | ||
| Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain | Q33987368 | ||
| Basics of the virology of HIV-1 and its replication | Q33990416 | ||
| Proteins that switch folds | Q34086494 | ||
| Structure-activity analysis of vinylogous urea inhibitors of human immunodeficiency virus-encoded ribonuclease H. | Q34108782 | ||
| Prediction of beta-turns | Q34254354 | ||
| Subunit-specific analysis of the human immunodeficiency virus type 1 reverse transcriptase in vivo. | Q34438247 | ||
| Protein folding and three-dimensional domain swapping: a strained relationship? | Q34525881 | ||
| Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5' '-(4' '-amino-1' ',2' '-oxathiole-2' ',2' '-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization. | Q34553499 | ||
| Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. | Q34575882 | ||
| Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase | Q34577497 | ||
| Novel HIV-1 reverse transcriptase inhibitors. | Q34756615 | ||
| Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules | Q34976859 | ||
| The unfolding story of three-dimensional domain swapping. | Q35080182 | ||
| Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission | Q35105679 | ||
| Conformation and dynamics of the Gag polyprotein of the human immunodeficiency virus 1 studied by NMR spectroscopy. | Q35212464 | ||
| A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses | Q35370552 | ||
| Mitochondrial toxicity of nrti antiviral drugs: an integrated cellular perspective | Q35550221 | ||
| Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer | Q35623899 | ||
| The p66 immature precursor of HIV-1 reverse transcriptase. | Q35638699 | ||
| Asymmetric conformational maturation of HIV-1 reverse transcriptase | Q35675915 | ||
| Mutagenesis of human immunodeficiency virus reverse transcriptase p51 subunit defines residues contributing to vinylogous urea inhibition of ribonuclease H activity | Q35763192 | ||
| Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase | Q35769639 | ||
| The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in rep | Q35794241 | ||
| The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. | Q35854362 | ||
| Structural integrity of the ribonuclease H domain in HIV-1 reverse transcriptase. | Q35875958 | ||
| ??? | Q57904706 | ||
| Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance | Q35914346 | ||
| Lethal mutagenesis of HIV. | Q36008905 | ||
| Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor | Q36018893 | ||
| Characterization of a folding intermediate from HIV-1 ribonuclease H | Q36280664 | ||
| Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase | Q36297904 | ||
| Structural basis of the allosteric inhibitor interaction on the HIV-1 reverse transcriptase RNase H domain. | Q36300994 | ||
| Metal and ligand binding to the HIV-RNase H active site are remotely monitored by Ile556 | Q36368801 | ||
| TSAO derivatives, inhibitors of HIV-1 reverse transcriptase dimerization: recent progress. | Q36489304 | ||
| Unfolding the HIV-1 reverse transcriptase RNase H domain--how to lose a molecular tug-of-war | Q36627970 | ||
| HIV reverse transcriptase structure-function relationships | Q36657162 | ||
| Efavirenz enhances HIV-1 gag processing at the plasma membrane through Gag-Pol dimerization | Q36667876 | ||
| Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance | Q36799767 | ||
| Protein-mediated antagonism between HIV reverse transcriptase ligands nevirapine and MgATP. | Q36939750 | ||
| Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. | Q37083800 | ||
| Nucleocapsid protein function in early infection processes | Q37086413 | ||
| Exploiting drug-resistant enzymes as tools to identify thienopyrimidinone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H. | Q37432679 | ||
| Therapeutic potential of peptide motifs against HIV-1 reverse transcriptase and integrase | Q37550911 | ||
| Formation of the tRNALys packaging complex in HIV-1. | Q37633035 | ||
| Implications of 3D domain swapping for protein folding, misfolding and function. | Q38040726 | ||
| Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: a two step process | Q38298949 | ||
| Buried surface analysis of HIV-1 reverse transcriptase p66/p51 heterodimer and its interaction with dsDNA template/primer | Q38307848 | ||
| Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization | Q38355667 | ||
| Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization | Q38358165 | ||
| Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures. | Q38587299 | ||
| Why Do We Need New Drug Classes for HIV Treatment and Prevention? | Q38605487 | ||
| MAPPIT (MAmmalian Protein-Protein Interaction Trap) as a tool to study HIV reverse transcriptase dimerization in intact human cells | Q39959363 | ||
| Myristoylation is required for human immunodeficiency virus type 1 Gag-Gag multimerization in mammalian cells | Q40078275 | ||
| Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance | Q40394618 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 260 | |
| P577 | publication date | 2016-09-27 | |
| P1433 | published in | Viruses | Q7935305 |
| P1476 | title | Structural Maturation of HIV-1 Reverse Transcriptase-A Metamorphic Solution to Genomic Instability | |
| P478 | volume | 8 |
| Q92675301 | Binding interface and impact on protease cleavage for an RNA aptamer to HIV-1 reverse transcriptase |
| Q38623200 | Identification of drivers for the metamorphic transition of HIV-1 reverse transcriptase |
| Q59359510 | Molecular Docking Studies of HIV-1 Resistance to Reverse Transcriptase Inhibitors: Mini-Review |
| Q92431103 | Spatial domain organization in the HIV-1 reverse transcriptase p66 homodimer precursor probed by double electron-electron resonance EPR |
| Q39065035 | Viral reverse transcriptases. |
Search more.